Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat

Diabetes and Vascular Disease Research

Volumn 7, Issue 1, 2010, Pages 20-27

  Dorafshar, Amir H ^a,b   Moodley, Kogie ^a   Khoe, Michelle ^a   Lyon, Chris ^a   Bryer Ash, Michael ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholine; Aorta; Insulin; Obesity; Thiazolidinedione

Indexed keywords

ACETYLCHOLINE; NITRIC OXIDE; PHENYLEPHRINE; PIOGLITAZONE; POTASSIUM CHLORIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN SENSITIVITY; MALE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; BLOOD PRESSURE; GLUCOSE TOLERANCE TEST; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NITROPRUSSIDE; OBESITY; PHENYLEPHRINE; POTASSIUM CHLORIDE; RATS; RATS, ZUCKER; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 77949409333     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109341688     Document Type: Article

References (46)

1. Gurnell, M, Savage, DB, Chatterjee, VK, O'Rahilly, S (2003) The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 88: 2412-2421.
2. Hsueh, WA, Quinones, MJ (2003) Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92(4A): 10J-7J.
3. Dandona, P (2002) Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions. Diabetes Technol Ther 4: 809-815.
4. Ginsberg, HN Insulin resistance and cardiovascular disease. (2000) J Clin Invest 106: 453-458.
5. Steinberg, HO, Chaker, H, Leaming, R, Johnson, A, Brechtel, G, Baron, AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610.
6. Subramanian, R, MacLeod, KM (2003) Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477(2): 143-152.
7. Andrews, TJ, Laight, DW, Anggard, EE, Carrier, MJ (2000) Investigation of endothelial hyperreactivity in the obese Zucker rat in-situ: reversal by vitamin E. J Pharm Pharmacol 52(1): 83-86.
8. Laight, DW, Kengatharan, KM, Gopaul, NK, Anggard, EE, Carrier, MJ (1998) Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol 125: 895-901.
9. Lebovitz, HE, Banerji, MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56: 265-294
10. Olefsky, JM, Saltiel, AR (2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11: 362-368.
11. Olefsky, JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106: 467-472.
12. Day, C (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16(3): 179-192.
13. Yoshimoto, T, Naruse, M, Nishikawa, M, et al. (1997) Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272(6 Pt 1): E989-E996.
14. Oakes, ND, Kennedy, CJ, Jenkins, AB, Laybutt, DR, Chisholm, DJ, Kraegen, EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43: 1203-1210.
15. Bowen, L, Stein, PP, Stevenson, R, Shulman, GI (1991) The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40: 1025-1030.
16. Ikeda, H, Taketomi, S, Sugiyama, Y, et al. (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40(2 Pt 1): 156-162.
17. Fujiwara, T, Yoshioka, S, Yoshioka, T, Ushiyama, I, Horikoshi, H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558.
18. Lehmann, JM, Moore, LB, Smith-Oliver, TA, Wilkison, WO, Willson, TM, Kliewer, SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956.
19. Yoshimoto, T, Naruse, M, Shizume, H, et al. (1999) Vasculoprotective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145(2): 333-340.
20. Caballero, AE, Saouaf, R, Lim, SC, et al. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52(2): 173-180.
21. Diep, QN, El Mabrouk, M, Cohn, JS et al. (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105: 2296-2302.
22. Fukunaga, Y, Itoh, H, Doi, K, et al. (2001) Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158(1): 113-119.
23. Avena, R, Mitchell, ME, Nylen, ES, Curry, KM, Sidawy, AN (1998) Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28: 1024-31; discussion 31-32.
24. Plutzky, J (2003) The potential role of peroxisome proliferator- activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 92(4A): 34J-41J.
25. Wakino, S, Law, RE, Hsueh, WA (2002) Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes Complications 16(1): 46-49.
26. Bagi, Z, Koller, A, Kaley, G (2003) Peroxisome Proliferator- Activated Receptor-{gamma} Activation Increases NO Bioavailability in Coronary Arterioles in Type 2 Diabetes by Reducing Oxidative Stress. Am J Physiol Heart Circ Physiol
27. Walker, AB, Chattington, PD, Buckingham, RE, Williams, G (1999) The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453.
28. Buchanan, TA, Meehan, WP, Jeng, YY, et al. (1995) Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360.
29. Pamidimukkala, J, Jandhyala, BS (1996) Evaluation of hemodynamics, vascular reactivity and baroreceptor compensation in the insulin resistant Zucker obese rats. Clin Exp Hypertens 18: 1089-1104.
30. Zemel, MB, Peuler, JD, Sowers, JR, Simpson, L (1992) Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support. Am J Physiol 262(3 Pt 1): E368-E371.
31. Hopfner, RL, Misurski, DA, McNeill, JR, Gopalakrishnan, V (1999) Effect of sodium orthovanadate treatment on cardiovascular function in the hyperinsulinemic, insulin- resistant obese Zucker rat. J Cardiovasc Pharmacol 34: 811-817.
32. Cox, RH, Kikta, DC (1992) Age-related changes in thoracic aorta of obese Zucker rats. Am J Physiol 262(5 Pt 2):H1548-H1556.
33. Walker, AB, Dores, J, Buckingham, RE, Savage, MW, Williams, G (1997) Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci (Lond) 93: 235-241.
34. Yoshioka, S, Nishino, H, Shiraki, T, et al. (1993) Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42(1): 75-80.
35. Kotchen, TA, Zhang, HY, Reddy, S, Hoffmann, RG (1996) Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270(3 Pt 2): R660-R666.
36. Verma, S, Bhanot, S, Arikawa, E, Yao, L, McNeill, JH (1998) Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 56(1): 7-16.
37. Moncada, S, Higgs, A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012.
38. Griendling, KK, FitzGerald, GA (2003) Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912-1916.
39. Rosen, P, Nawroth, PP, King, G, Moller, W, Tritschler, HJ, Packer, L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17: 189-212.
40. Vendrov, AE, Hakim, ZS, Madamanchi, NR, Rojas, M, Madamanchi, C, Runge, MS (2007) Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 27: 2714-2721.
41. Beckman, JS, Koppenol, WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271(5 Pt 1): C1424-C1437.
42. Zou, MH, Cohen, R, Ullrich, V (2004) Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 11(2): 89-97.
43. White, CR, Brock, TA, Chang, LY, et al. (1994) Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A 91: 1044-1048.
44. Zanetti, M, Sato, J, Katusic, ZS, O'Brien, T (2001) Gene transfer of superoxide dismutase isoforms reverses endothelial dysfunction in diabetic rabbit aorta. Am J Physiol Heart Circ Physiol 280: H2516-H2523.
45. Wilcox, R, Kupfer, S, Erdmann, E (2008) Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 155: 712-717.
46. Dormandy, JA, Charbonnel, B, Eckland, DJ, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366: 1279-1289.